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Abstract 
Many disease-causing missense mutations affect intrinsically disordered regions (IDRs) 
of proteins. Since these mutations do not affect protein structure, the molecular 
mechanism of their pathogenicity is enigmatic. Here, we employ a peptide-based 
proteomic screen to investigate the impact of mutations in IDRs on protein-protein 
interactions. We find that mutations in disordered cytosolic regions of three 
transmembrane proteins (GLUT1, ITPR1 and CACNA1H) lead to an increased binding 
of clathrin. In all three cases, the mutation creates a dileucine motif known to mediate 
clathrin-dependent trafficking. Follow-up experiments on GLUT1 (SLC2A1), the glucose 
transporter causative of GLUT1 deficiency syndrome, revealed that the mutated protein 
mislocalizes to intracellular compartments in a model cell line and in patient-derived 
induced pluripotent stem cells. Mutant GLUT1 interacts with adaptor proteins (APs) in 
vitro, and knocking-down AP-2 reverts the cellular mislocalization and restores glucose 
transport. A systematic analysis of other known disease-causing variants revealed a 
significant and specific overrepresentation of gained dileucine motifs in structurally 
disordered cytosolic domains of transmembrane proteins. Thus, several mutations in 
disordered regions appear to cause “dileucineopathies”. 
 
Highlights: 
- A peptide-based screen detects how mutations affect protein-protein interactions 
- Several pathogenic mutations create dileucine motifs and recruit clathrin 
- A dileucine motif gain in GLUT1 causes mistrafficking in GLUT1 deficiency 
syndrome    
- Dileucine motif gains recurrently occur in pathogenic mutations          
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Introduction 
Genome sequencing technologies have greatly facilitated the discovery of human 
protein variants. In many cases it is not known whether such variants cause disease, 
and even when associations have been established, determining the molecular 
mechanisms remains a major challenge (Cooper and Shendure, 2011). Most disease-
causing missense mutations affect evolutionarily conserved amino acids within 
structured regions of proteins and destabilize their structure (Subramanian and Kumar, 
2006; Yue et al., 2005). However, over 20% of human disease mutations occur in so 
called intrinsically disordered regions (IDRs) (Vacic et al., 2012). Contrary to the 
traditional understanding of protein structure and function, it is now clear that IDRs 
represent a functionally important and abundant part of eukaryotic proteomes (Uversky 
et al., 2008; Wright and Jane Dyson, 2014). Yet, since IDRs lack a defined tertiary 
structure and are typically poorly conserved, the classical structure-function paradigm 
cannot explain how mutations in IDRs cause disease. 
 
We set out to investigate the mechanism of these mutations by analyzing protein-
protein interactions (PPIs), which can help to understand how mutations cause disease 
(Ryan et al., 2013; Wang and Marcotte, 2010). The role of PPIs in disease is highlighted 
by the enrichment of missense mutations in interaction interfaces of proteins associated 
with the corresponding disorders (Wang et al., 2012). Moreover, comparing the 
interaction partners of wild-type proteins and their disease-associated variants can 
reveal disease mechanisms (Hosp et al., 2015; Zhong et al., 2009). We therefore 
sought to systematically investigate how mutations in IDRs affect PPIs. 
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IDRs often harbor short linear motifs (SLiMs) that mediate their function (Fuxreiter et al., 
2007; Van Roey et al., 2014). These SLiMs typically fall into two major classes -- motifs 
that mediate interactions with globular domains and/or motifs which harbor 
posttranslational modification sites (Tompa et al., 2014). Mutations in IDRs can cause 
disease by disrupting such motifs or by creating novel ones. A number of examples of 
such pathogenic changes in motifs have been reported (Cordeddu et al., 2009; 
Kadaveru et al., 2008; Silvis et al., 2003; Vogt et al., 2005). Additionally, computational 
studies have revealed that pathogenic mutations often occur in SLiMs (Narayan et al., 
2016; Radivojac et al., 2008; Uyar et al., 2014). Despite these insights, however, there 
has not yet been a systematic experimental analysis of how disease-causing mutations 
in IDRs affect interactions. One reason for this is that the small binding area between 
SLiMs and cognate domains results in low binding affinities, which makes it difficult to 
study these interactions (Neduva and Russell, 2005). 
 
Here, we developed a scalable proteomic screen using synthetic peptides to assess the 
impact of missense mutations in disordered regions on PPIs. By applying this screen to 
over 120 known disease-causing mutations we obtained a network of PPIs that are lost 
or gained as the result of mutations in disordered regions. Within this network, we 
identified a subnetwork comprising three mutations and five interacting proteins 
enriched in terms related to clathrin-dependent trafficking. Intriguingly, all three 
mutations in this subnetwork create novel dileucine motifs in cytosolic tails of 
transmembrane proteins. Since dileucine motifs mediate clathrin-dependent trafficking, 
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our findings may provide a mechanistic explanation about how these mutations cause 
disease. Indeed, experiments on the glucose transporter GLUT1 confirmed that the 
gained dileucine motif causes protein mislocalization by recruiting adaptor proteins and 
inducing clathrin-dependent endocytosis. In summary, we show that our scalable 
proteomic screen can reveal the functional consequences of mutations in disordered 
regions. Moreover, the data suggest that dileucine motif gains in disordered cytosolic 
tails of transmembrane proteins are a relatively frequent - and potentially druggable - 




A peptide-based interaction screen of disease-causing mutations 
We reasoned that quantitative interaction proteomics with immobilized synthetic 
peptides should enable us to systematically assess the impact of mutations in IDRs. 
Such peptide pull-downs can maintain specificity even in the setting of low affinity 
interactions (Schulze and Mann, 2004). We therefore designed a scalable proteomic 
screen that employs peptides synthesized on cellulose membranes (Fig. 1 A). These 
membranes carry peptides with 15 amino acids that correspond to IDRs in both the 
wild-type and mutant form. Membranes are incubated with cell extracts to pull-down 
interacting proteins. After washing, peptide spots are excised and the proteins 
associated with them are identified and quantified by shotgun proteomics. 
 
The main challenge in such interaction screens is to distinguish specific interaction 
partners from non-specific contaminants (Gingras and Raught, 2012; Gstaiger and 
Aebersold, 2009; Meyer and Selbach, 2015; Smits and Vermeulen, 2016). We 
addressed this challenge through the use of two levels of quantification. First, two 
replicates of a pull-down with a specific peptide sequence are compared to all other 
peptide pull-downs via label-free quantification (LFQ) (Cox et al., 2014). This LFQ-filter 
selects proteins that bind specifically to a given peptide. Secondly, the screen employs 
SILAC-based quantification (Mann, 2006) to identify differential interaction partners of 
the wild-type and disease-causing form of a peptide. This strategy requires incubating 
the two replicates of the membrane with cell lysates that have been differentially SILAC 
labeled. Wild-type peptide spots from the heavy pull-down are combined with spots from 
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the light pull-down that correspond to the mutant forms of the same peptide, and vice 
versa. SILAC ratios give a measure of the degree to which each particular mutations 
affects a specific interaction. 
 
For the screen we selected 128 mutations in IDRs which are known to cause 
neurological diseases (Fig. S1, Table S1). We included a peptide from an IDR in the 
SOS1 protein that contains a proline-rich motif by which it is known to recruit several 
specific binders via their SH3 domains (Schulze and Mann, 2004). We analysed the 2 x 
129 pull-down samples by using high-resolution shotgun proteomics in 45 min runs, 
resulting in a total measurement time of about eight days. Replicates of the same 
peptide clustered with a median correlation coefficient (Pearson’s R) of 0.87, indicating 
good reproducibility (Fig. S2A). The LFQ data identified nine specific interactors of the 
SOS1 peptide, including four of the five that were previously known (Fig. 1 B). In the 
corresponding SILAC data, seven of the nine LFQ-specific binders show preferential 
binding to the wild-type compared to the mutant which contains a disrupted proline-rich 
motif (Fig. 1 C). Importantly, all interactors that are both specific (LFQ) and differential 
(SILAC) contain SH3 domains. To further assess the relationship between peptide 
motifs and cognate domains we also analyzed all pull-downs combined. We found that 
mutations which disrupt a predicted SLiM in the peptide tend to reduce binding of 
proteins with cognate domains (Fig. S2B). Conversely, the gain of a SLiM in a peptide 
tends to increase binding to proteins with matching domains. In summary, these data 
demonstrate that our screen efficiently detects how mutations in IDRs affect interactions 
mediated by SLiMs. 
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A quantitative interaction network for disease-associated IDRs 
Individual pull-downs typically led to the identification of ~400 proteins. If all of these 
proteins were considered specific binders, this would correspond to ~400 binary 
interactions per pulldown and a total of more than 100,000 interactions. However, since 
many proteins are in fact background binders, we applied our quantitative filters with 
cut-offs derived from the SOS1 control peptide (Fig. 2 A). About half of the 2 x 128 
peptides showed at least one specific binder according to the LFQ-filter (Fig. S2C). 
Applying the LFQ-filter dramatically reduced the total number of interactions to 618. All 
of these 618 interactions are specific for the wild-type and/or the mutant form of a 
peptide as compared to all other peptides in the screen (Table S2). However, not all of 
these specific interactions are differential, i.e. affected by the mutation. Therefore we 
next applied the SILAC-filter, which led to a final list of 180 differential interactions 
(Table S3). 111 of these interactions are lost through mutations in the peptide, while 69 
are gained. Of note, since pull-downs can also capture indirect binders, not all of these 
interactions are necessarily direct. 
 
To provide an overview of the data we displayed all of the differential interactions as a 
network (Fig. 2 B). This revealed that several wild-type or mutant peptides shared 
differential interactors, suggesting functional similarities. Moreover, subnetworks were 
enriched in specific gene ontology terms (supplemental dataset “GOtermClusters.pdf”). 
Figure 2 B highlights two subnetworks that we find particularly interesting (insets) : One 
is enriched in proteins connected to clathrin-coated vesicles (see below). The other is 
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enriched in splicing factors that interact with an IDR corresponding to amino acids 512-
526 of fused in sarcoma (FUS). These interactions are disrupted by the R521C 
mutation. FUS is an RNA-binding protein implicated in amyotrophic lateral sclerosis 
(ALS) (Deng et al., 2014). R521C and other mutations in the C-terminal region of the 
protein are thought to be pathogenic because they disrupt a nuclear localization signal 
(Dormann et al., 2010). Our data suggests that impaired binding of splicing factors could 
be an additional/alternative explanation for the pathogenicity of this mutation. This 
observation is interesting because FUS has already been implicated in splicing (Ishigaki 
et al., 2012; Qiu et al., 2014; Rogelj et al., 2012). In fact, the C-terminal region of the 
protein was found to interact with serine/arginine-rich splicing factor 10 (SRSF10) even 
before pathogenic mutations in this region were identified (Yang et al., 1998). 
 
Recruitment of clathrin through gains of dileucine motifs   
The finding we considered most interesting is that mutated IDRs from CACNA1H, 
GLUT1/SLC2A1 and ITPR1 lead to specific interactions with clathrin (Fig. 3 A). The 
corresponding SILAC data revealed that, in all three cases, clathrin exhibited a strong 
preference for the mutant form of the peptides over the wild-type (Fig. 3 B). Since 
clathrin mediates endocytosis and intracellular trafficking of transmembrane proteins, 
our finding suggests that these mutations might affect protein trafficking. Intriguingly, the 
three mutations share other features beyond an increased affinity for clathrin: First, all 
three mutations affect transmembrane proteins -- a calcium channel (CACNA1H) and a 
glucose transporter (GLUT1) residing in the plasma membrane and an inositol 1,4,5-
trisphosphate receptor (ITPR1) located mainly in the endoplasmic reticulum (ER) (Fig. 3 
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C). Second, all three mutations affect disordered regions exposed to the cytosol, which 
makes them accessible to cytosolic adaptor proteins that mediate clathrin recruitment. 
Third, all three mutations involve the change of a proline to a leucine residue and 
thereby result in the appearance of a novel dileucine motif (“LL”) in the IDR (Fig. 3 D). 
Such motifs are known to recruit clathrin to the plasma membrane or intracellular 
locations (Pandey, 2009). The classical dileucine motif is [D/E]XXXL[L/I] (Dinkel et al., 
2015), but variations of this theme are common (Kozik et al., 2010; Pandey, 2009; 
Staudt et al., 2016; Traub, 2009). 
 
A dileucine motif gain causes mislocalization of the glucose 
transporter GLUT1 
To assess the functional significance of the dileucine motif gains and clathrin 
recruitment we selected the P485L mutation in GLUT1/SLC2A1. This mutation causes 
GLUT1 deficiency syndrome (G1DS), a disorder characterized by seizures and 
intellectual disability with onset in early infancy (De Vivo et al., 1991; Leen et al., 2010a; 
Pascual et al., 2008). GLUT1 is mainly expressed in endothelial cells that form the 
blood-brain-barrier and in astrocytes, facilitating glucose entry into the brain. Pathogenic 
mutations in GLUT1 impair cerebral glucose flux, leading to permanent encephalopathy. 
 
To determine the impact of the P485L mutation on the subcellular localization, we first 
generated stable inducible cell lines expressing epitope tagged full-length wild-type or 
mutant GLUT1. While the wild-type protein mainly localized to the plasma membrane, 
the P485L mutant displayed an intracellular pattern (Fig. 4 A). Hence, the mutation 
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indeed appears to cause protein mislocalization. Colocalization experiments with 
several markers confirm that mutated GLUT1 localizes to endocytic compartments (Fig. 
4 B, S3). To more systematically characterize the cellular compartment in which 
GLUT1_P485L resides, we used BioID as a proximity labeling method (Roux et al., 
2012) (Table S4). We performed this experiment in a comparative manner for both wild-
type and mutant GLUT1 using SILAC-based quantification (see Methods). Mutated 
GLUT1 colocalized with proteins involved in membrane trafficking, clathrin-mediated 
endocytosis, and post-Golgi trafficking (Fig. 4 C). In contrast, wild-type GLUT1 
colocalized with plasma membrane-associated proteins. 
 
Adaptor proteins bind to mutant GLUT1 and cause cellular 
mistrafficking 
The BioID experiment identified several subunits of the heterotetrameric vesicular 
transport adaptor proteins (APs). This finding is particularly relevant because AP-1, AP-
2 and AP-3 directly bind to both dileucine motifs and clathrin to mediate cellular 
transport (Traub and Bonifacino, 2013): Binding of AP complexes to the cargo triggers a 
conformational change, which opens up the AP complex. It now exposes a 'Clathrin box 
motif' that leads to recruitment of clathrin, which begins to surround the emerging 
vesicle bud as a second protein layer. 
 
Intriguingly, all subunits of AP-1, AP-2 and AP-3 that we identified showed increased 
co-localization with mutated over wild-type GLUT1 in both the forward and reverse (that 
is, SILAC label swap) BioID experiment (Fig. 5 A). We therefore tested whether the 
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cytosolic tail of GLUT1 can interact with APs in vitro (Fig. 5 B). We found that mutated 
but not wild-type GLUT1 pulled down both AP-1 and AP-2. Together, these results show 
that the mutation causes association of GLUT1 with APs, providing a molecular 
explanation for mistrafficking. Since we did not detect APs as hits in our original screen, 
we designed targeted assays against peptides from several APs based on their known 
fragmentation spectra (Zauber et al., 2018). Repeating the peptide pull-downs for 
GLUT1, CACNA1H and ITPR1 with targeted proteomics as read-out, confirmed that 
several APs preferentially interact with the mutated peptides (Fig. S4).  
 
APs localize to different intracellular compartments and mediate membrane trafficking in 
distinct pathways (Park and Guo, 2014a). For example, AP-2 mediates clathrin-
dependent endocytosis at the plasma membrane (McMahon and Boucrot, 2011; 
Pandey, 2009; Staudt et al., 2016; Traub, 2009). The interaction of GLUT1_P485L with 
AP-2 therefore suggests that internalization of the protein from the plasma membrane 
contributes to its mislocalization. To test whether mutant GLUT1 is taken up via 
endocytosis we added fluorescently labeled transferrin to GLUT1 expressing cells. 
Mutant but not wild-type protein extensively colocalized with endocytosed transferrin 
(Fig.5 C and D). Finally, if the P485L mutation causes GLUT1 endocytosis via AP-2, 
inhibiting AP-2 function should restore the correct subcellular localisation. We therefore 
used siRNAs to knock-down AP-2 (Fig. 5 E). Consistent with our prediction, loss of AP-
2 expression rescued the mislocalization of mutated GLUT1 (Fig. 5 F). We also tested 
the ability of stable cell lines inducibly expressing GLUT1 to take-up radiolabeled 
glucose. Cells expressing the mutated proteins showed significantly reduced glucose 
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uptake, which was rescued by knocking down AP-2 (Fig. 5 G). Thus, the P485L mutant 
can apparently sustain normal glucose uptake when the protein is located in the plasma 
membrane. Together, these data show that the dileucine motif gain indeed causes 
clathrin-dependent endocytosis and mistrafficking of GLUT1. 
 
GLUT1 P485L mislocalizes in patient-derived iPSCs 
The experiments described so far are based on in vitro assays or cell line models 
expressing tagged variants of GLUT1. We therefore sought to validate our findings by 
analyzing the behaviour of endogenous GLUT1 in patient cells. To this end, we 
obtained fibroblasts from a GLUT1 deficient patient harboring the P485L mutation via a 
skin punch biopsy (see Methods). We then reprogrammed these fibroblasts into induced 
pluripotent stem cells (iPSCs) by RNA-based transfer of pluripotency factors (Fig. 6 A). 
The clones obtained showed characteristic expression of pluripotency markers (Fig. 
S5). We then analyzed the subcellular distribution of GLUT1 in these cells. While 
GLUT1 was mainly localized in the plasma membrane of control iPSCs, patient-derived 
cells showed characteristic intracellular accumulations (Fig. 6 B). Co-staining with a 
post-Golgi SNARE revealed extensive colocalization (Kreykenbohm et al., 2002) (Fig. 6 
C). Of note, the patient-derived iPSCs also showed GLUT1 signal at the plasma 
membrane. This is consistent with the fact that only one GLUT1 allele in the patient is 
affected (Leen et al., 2010a; Pascual et al., 2008; Slaughter et al., 2009). In summary, 
these data show that the mislocalization observed in HEK cells can be reproduced in 
patient cells.  
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GLUT1 P485L localization at the blood-brain-barrier is perturbed in 
vivo 
Next, to study the P485L mutation in vivo, we used CRISPR/Cas9 to generate the 
corresponding mutant in the mouse genome (Fig. 6 E). Heterozygous mice were viable, 
fertile and did not display any obvious phenotype. However, out of 6 heterozygous 
crossings, we failed to detect any born homozygous mutant pup. A detailed inspection 
of maternal delivery illustrated that homozygous mutant pups come to term but die 
immediately after birth and are removed from the litter by the dams. To histologically 
analyze GLUT1 distribution in the endothelial cells of the blood-brain-barrier, we 
dissected embryonic (E) day 14.5-15.5 mice and stained their cerebral cortex with 
antibodies against GLUT1. We co-stained with anti-ICAM2 to label the luminal plasma 
membrane and isolectin B4 (IB4) to label the entire endothelial plasma membrane. We 
observed an overall reduction in GLUT1 staining in heterozygous and homozygous 
animals with otherwise largely normal vascular morphology (Fig. 6 F). High resolution 
STED imaging revealed a strong reduction in the density of GLUT1 clusters in 
endothelial plasma membranes of homozygous mutant mice compared to wild type 
littermates (Fig. 6 G and H). Hence, the P485L mutation also reduces GLUT1 levels in 
the plasma membrane in vivo.   
 
Gains in dileucine motifs as a general disease mechanism 
We next investigated whether dileucine motif gains represent a more general disease 
mechanism. To test this, we conducted a search of missense mutations known to cause 
disease and that occur within disordered cytosolic regions of transmembrane proteins. 
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We found four additional pathogenic dileucine motif gains in the Humsavar database 
(Fig. 7 A, Table S5). The same search in the ClinVar database returned four additional 
mutations. For example, two dileucine motif gains affect cytosolic regions of the cystic 
fibrosis transmembrane conductance regulator (CFTR) and cause cystic fibrosis (Figure 
S6A, Table S5). In total, these 11 mutations affect 6 different proteins and cause a wide 
range of diseases. 
Since we focused our follow-up experiments on GLUT1, we cannot state with certainty 
that the other dileucine motif gains also cause protein mistrafficking. Alternatively, the 
mutations could cause disease by different mechanisms and might just create dileucine 
motifs as a by-product. If that was the case, dileucine motifs should be homogeneously 
distributed between disease-causing mutations and non-pathogenic polymorphisms. In 
contrast, if dileucine motif gains are responsible for pathogenesis, they would be 
predicted to occur more often in disease than in non-pathogenic variants. Moreover, 
pathogenic dileucine motif gains should be specific for cytosolic regions of 
transmembrane proteins since this is where they exert their function. To test these 
predictions, we compared the frequency of dileucine motif gains that have been found in 
disease-causing mutations to their appearance in non-pathogenic polymorphisms (from 
Humsavar). A global survey of all disordered regions of the entire proteome revealed 
that gains in dileucine motif gains occurred at about the same rate in disease and non-
pathogenic variants (OR = 0.81, p-value = 0.319, two-sided Fisher’s Exact Test). In the 
cytosolic tails of transmembrane proteins, however, we observed a 3.7-fold enrichment 
of dileucine motifs implicated in disease (OR = 3.7, p-value = 0.017, two-sided Fisher’s 
Exact Test, Fig. 7 B). Disordered extracellular regions of transmembrane proteins do 
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not show this enrichment. Performing the equivalent analysis with the ClinVar database 
yielded similar results (Figure S6B). We conclude that dileucine motif gains in 
disordered regions of the cytosolic segments of transmembrane proteins are 
significantly and specifically enriched in disease. To further assess the significance of 
this finding, we systematically searched within cytosolic regions of transmembrane 
proteins for all other annotated SLiMs contained in the ELM database (Dinkel et al., 
2015). Intriguingly, of all 263 SLiMs tested, the dileucine motif (LIG_diLeu_1) was the 
only significantly enriched motif in disease (Fig. 7 C).  
 
Finally, to test if some of the additional dileucine motif gains can cause mistrafficking 
similar to GLUT1, we performed antibody feeding experiments. To this end, we created 
chimeric proteins consisting of the IL-2 receptor alpha chain (TAC) fused to mutated 
and wild-type cytosolic regions of the respective disease protein (see Methods). Cells 
expressing these constructs are incubated with antibodies against the extracellular 
region of TAC and allowed to endocytose the chimeric proteins together with bound 
antibodies. A specific staining protocol is then used to exclusively detect internalized 
antibodies (Diril et al., 2009). We generated fusion proteins for GLUT1 (as positive 
control) and seven additional dileucine motif gains. Four of the seven mutations resulted 
in increased internalization relative to the corresponding wild-type sequences (Fig. 7 D). 
In addition, we observed mutant-specific interaction of AP-1 and/or AP2 for several 
selected cytosolic regions in in vitro interaction assays (Fig. S6D). Collectively, these 
results indicate that several additional pathogenic dileucine motif gains cause protein 
mistrafficking.      
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Discussion 
Understanding the functional relevance of protein variants is a major challenge in the 
era of personal genomics -- especially for missense mutations in disordered regions. 
Our proteomic screen provides a first systematic experimental analysis of how 
mutations in disordered regions affect protein-protein interactions. Our results show that 
the method can (i) capture known interactions, (ii) detect how mutations in SLiMs affect 
binding of cognate domains and (iii) provide novel mechanistic insights into 
pathogenesis. The peptide-based method is especially useful for mutations in proteins 
that are otherwise difficult to study, such as large transmembrane proteins. 
Nevertheless, it is also important to consider the intrinsic limitations of the approach. 
Most importantly, in vitro pull-downs do not necessarily reflect physiological interactions 
in vivo. For example, artifactual binding can occur when combining peptides and 
proteins that never meet each other in the cell (Gibson et al., 2015). Moreover, taking 
IDRs out of the context of the full length protein and immobilizing them as short peptides 
can affect interactions. Finally, amino acids within IDRs often carry posttranslational 
modifications -- a possibility which we did not consider here. In the future, it will be 
interesting to include modified peptides, especially since mutations often affect 
modification sites (Narayan et al., 2016; Radivojac et al., 2008). 
 
Our screen revealed that three mutations in cytosolic tails of transmembrane proteins 
create dileucine motifs and lead to increased binding of clathrin. Follow-up experiments 
demonstrated that the dileucine motif gain in GLUT1 causes mislocalization from the 
plasma membrane to endocytic compartments. We also observed that mutated GLUT1 
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recruits several adaptor proteins (AP-1, AP-2 and AP-3), thus providing a direct link 
between the motif gain, clathrin recruitment and GLUT1 mistrafficking. Furthermore, 
knocking-down AP-2 rescued mislocalization of mutated GLUT1 and restored glucose 
transport. This finding shows that the aberrant trafficking is -- at least partially -- due to 
increased endocytosis. However, it should be kept in mind that AP-1 and AP-3 mediate 
other trafficking events such as transport between endosomes and the trans-Golgi 
network or transport to lysosomes (Dell’Angelica, 2009; Park and Guo, 2014). The 
observation that mutated GLUT1 also interacts with these APs therefore suggests that 
other trafficking events may also be perturbed. 
The finding that pathogenic mutations in cytosolic tails of other transmembrane proteins 
also create dileucine motifs is particularly intriguing. We term diseases caused by such 
motif gains “dileucineopathies”. Whether the other dileucine motif gains cause protein 
mislocalization similar to GLUT1 remains to be investigated. The observation that these 
mutations are significantly and specifically enriched in cytosolic domains suggests that 
at least some of them are functional. Also, we find that four out of seven tested 
mutations increase internalization of chimeric proteins in antibody feeding experiments. 
This further supports the view that at least some pathogenic dileucine motif gains cause 
disease by inducing protein mistrafficking. However, more detailed follow-up 
experiments are required to test this hypothesis for individual mutations. It is also 
interesting to note that a pathogenic mutation in the cystic fibrosis transmembrane 
conductance regulator (CFTR) has been reported to generate a tyrosine-based 
internalization motif (Silvis et al., 2003).  
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Why are dileucine-motif gains a recurrent cause of disease? We think this is due to a 
combination of several factors: First, dileucine motifs are not very complex and can thus 
easily arise by chance. Second, proline codons can mutate to leucine codons by 
changing a single nucleotide. Third, proline is overrepresented in IDRs, which are also 
the sites where the motif needs to be located in order to be functional. Since the genetic 
cause of many diseases has not yet been identified (Boycott et al., 2013), we expect 
that more pathogenic dileucine motif gains will soon emerge. Knowing that such gains 
can be pathogenic will make it easier to classify them as disease-causing among the 
many variants present in the human population (Cooper and Shendure, 2011). The 
observation that GLUT1 mislocalization and glucose transport can be rescued suggests 
that pathogenic dileucine motif gains may be druggable. Whether patients with 
“dileucineopathies” might benefit from inhibiting specific clathrin-dependent trafficking 
events remains to be investigated. 
 
Bioinformatic studies have established that pathogenic mutations in disordered regions 
often affect SLiMs (Narayan et al., 2016; Radivojac et al., 2008; Uyar et al., 2014). 
However, whether these predicted motif changes really affect protein-protein 
interactions has not yet been investigated systematically. Moreover, many motifs have 
not yet been defined and thus escape computational predictions (Tompa et al., 2014). 
The biochemical approach presented here provides a useful complementary strategy to 
computational studies. Key advantages of our setup are its scalability (by using 
synthetic peptides) and specificity (by employing two quantitative filters). While we 
focused on neurological disorders here, the approach can also be applied to other types 
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Fig. 1: Quantitative interaction screen with disease-associated disordered regions 
A, Cellulose membranes with synthetic wild-type (circles) and mutated (stars) peptides 
are incubated with lysate from light (light blue) or heavy (dark blue) SILAC labelled cells 
to pull-down interacting proteins. Spots are excised, corresponding wild-type/mutant 
pairs are combined and analyzed by quantitative shotgun proteomics (represented by 
an Orbitrap). Middle panels: Label free quantification (LFQ) identifies specific interactors 
by comparing both replicates to all other pull-downs. Volcano plots depict protein 
enrichment in in the two replicate pull-downs of a given peptide over all other peptide 
pull-downs (x axis shows mean log2FC, y axis shows -log10 p-values), separately for 
the wild-type (left) and mutant peptide (right). The threshold (red lines) was derived from 
the benchmark experiment with the SOS1 peptide (Fig. 1B, for details see Material and 
Methods). LFQ-specific interactors are depicted in red. SILAC-based quantification 
identifies differential binders by directly comparing corresponding wild-type and mutant 
pairs. Differential binders of the wild-type and mutant peptide appear in the upper-right 
and lower-left quadrants, respectively (for detailed selection criteria see Methods). B, C 
Results for a SOS1-derived peptide with a SH3 domain-binding PxxP motif as a 
benchmark. B, Volcano plot from the LFQ data for wild-type SOS1. Specific binders are 
shown as red dots. 4 out of 5 known binders (red gene names) are detected. C, SILAC 
log2 fold changes for differential binders of the wild-type and mutant SOS1 peptide. 
Proteins with SH3 domains are shown with black outlines. 
 
Fig. 2: Differential interactors of wild-type and mutant IDRs  
A, Quantitative filters to select specific and differential interactions. Only a minor fraction 
of all detected interactions is specific (LFQ filter). Moreover, only a fraction of specific 
interactions are differential (SILAC filter), i.e. show preferential binding to the wild-type 
or mutant form of a peptide. Mutation-induced interaction losses are more frequent than 
mutation-induced gains.     
B, Network of all differential interactions. Peptides (rectangles) and interacting proteins 
(ovals) are presented as nodes. The edges indicate preferential binding to the wild-type 
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(blue) or mutant (red) form of a peptide (edge width indicates SILAC ratios). Highlighted 
subnetworks are enriched in splicing regulators and clathrin-coated vesicle proteins 
(see text). 
 
Fig. 3: Recruitment of clathrin by recurrent gains of dileucine motifs 
A, Volcano plots for pull-downs with mutated peptides derived from CACNA1H, GLUT1 
and ITPR1. Specific binders (relative to all other pull-downs) are highlighted in red. All 
three peptides specifically interact with clathrin. 
B, Corresponding SILAC plots show that clathrin and related proteins preferentially bind 
to the mutant form of peptides (relative to the wild-type). 
C, Graphical representation of the mutation sites. All three mutations affect cytosolic 
regions of transmembrane proteins. CACNA1H and GLUT1 are located mainly in the 
plasma membrane and ITPR1 mainly in the ER. 
D, Aligning the three peptide sequences reveals a common gain of a dileucine motif. 
 
Fig. 4: A mutation-induced dileucine motif gain causes mislocalization of the 
glucose transporter GLUT1 
A, Confocal images of GLUT1 localization in HEK cells, stably expressing FLAG-
GLUT1, reveal that the wild-type is localized mainly at the cell membrane while the 
P485L mutant is mislocalized to endocytic compartments. (FLAG-GLUT1: green, DAPI: 
blue). Scale bars: 10 µm. B, Colocalization analysis shows extensive colocalization of 
mutant, but not wild-type GLUT1 with markers of several endocytic compartments. 
Pearson’s thresholded coefficients (as implemented in the Imaris software) was 
determined for GLUT1 variants with the indicated proteins. Depicted are mean values, 
error bars show standard deviations of the mean. For exemplary images see Fig. S3. 
C, Comparison of proteins colocalizing with wild-type and mutant GLUT1 by proximity 
labeling (BioID). The upper left panel shows SILAC log2 fold changes from two replicate 
experiments with swapped isotope labels. Blue and red labeled proteins are enriched by 
wild-type GLUT1 or mutant GLUT1, respectively. The ten most significant cellular 
component GO-terms reveal that mutated GLUT1 is involved in clathrin dependent 
processes and endosomal trafficking. In contrast, wild-type GLUT1 colocalizes with 
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plasma membrane-associated proteins. The lower panel is colored according to the top 
three enriched GO-terms and shows the variants typical subcellular compartments. 
Figure adapted from (Raiborg and Stenmark, 2009). 
 
Fig. 5: Adaptor proteins bind to mutated GLUT1 and cause cellular mistrafficking 
A, Adaptor protein complexes AP-1, AP-2 and AP-3 show increased colocalization to 
GLUT1 due to P485L mutation in replicates of BioID experiment from Fig. 4. Identified 
subunits of APs are shown in red. 
B, P485L mutant but not wild-type Glut1 C-terminal tail interacts with AP-1 and AP-2. 
Tails were tagged with GST to pull-down interaction partners from mouse brain lysate. 
Talin is shown as a negative control and is not pulled down from either of the two 
variants.  
C, D, Mutant but not wild-type GLUT1 extensively colocalizes with endocytosed 
transferrin. HEK cells stably expressing FLAG-GLUT1 are incubated with fluorescently 
labeled transferrin for 10 min before fixation. Scale bar: 10 μm. E, F, Western-blot 
against AP-2 α and μ subunits shows downregulation after two rounds of siRNA 
transfection against AP-2 μ. AP-2 knock-down leads to relocalization of GLUT1_P485L 
to the plasma membrane and hence rescue of the mutation phenotype. Scale bar: 10 
μm. G, Radioactive glucose uptake after AP-2 knock-down leads to rescue of glucose 
uptake deficit of GLUT1_P485L. GLUT1 expression was induced by addition of 
doxycycline and glucose uptake was inhibited by addition of cytochalasin B. % glucose 
uptake is relative to GLUT1 wild-type, +doxycycline, -cytochalasin B. Depicted are mean 
values over technical triplicates of three independent experiments. Error bars: SEM. ∗p 
value <0.05, ** p value <0.01 from a paired, one-sided t-test. 
 
Fig. 6: GLUT1 P485L mislocalizes in patient-derived iPSCs and endothelial cells 
of the blood-brain barrier in mice  
A, A skin sample was taken from a GLUT1 deficiency patient with a heterozygous 
GLUT1_P485L mutation. Fibroblasts were grown and reprogrammed to iPSCs. 
B, Heterozygous GLUT1_P485L mutation leads to partial mislocalization of GLUT1 in 
patient-derived iPSCs. Scale bars: 10 μm. 
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C, D, GLUT1_P485L colocalizes with the post-Golgi SNARE VTI1A. Scale bar: 10 μm. 
E, A mouse carrying the GLUT1 P485L mutation was created by CRISPR/Cas9 
targeted method. PAM sequence and gRNA are marked in targeted region of SLC2A1 
(GLUT1 gene). Sanger sequencing confirmed insertion of mutation (chromatogram: 
A=green, T=red, C=blue, G=black). F, Immunohistological analyses of cortical slices of 
wild-type, heterozygous and homozygous GLUT1 mutant mice using antibodies against 
GLUT1 (red) and DAPI (blue) as counterstain (left panels); a higher magnification of a 
vessel stained by antibodies against GLUT1 (red), IB4 (green) and ICAM2 (blue) is 
shown in the right panels. G, Representative STED images of transverse cross-sections 
through brain vessels of wild type (+/+), heterozygous (+/P485L) and homozygous 
(P485L/P485L) mutant mice stained with isolectin B4 and antibodies against GLUT1 
and ICAM2. Insets show a fragment of abluminal membrane (IB4 positive, ICAM2 
negative) indicated with a black box. Scale bars: 2 µm (main panels) and 0.25 µm 
(insets). H, Quantification of Glut1 signal relative to IB4 signal in vessel membranes (n – 
number of vessels per genotype, N – number of animals per genotype). Boxplot central 
line indicates the median, the bottom and top edges of the box indicate the 25th and 
75th percentiles, respectively.  
Fig. 7: Mutation-induced gains of dileucine motifs are a significant cause of 
disease 
A, A systematic bioinformatic search revealed four additional pathogenic mutations in 
cytosolic segments of transmembrane proteins that create dileucine motifs. 
B, Relative frequency of dileucine motif gains in disease mutations and polymorphisms 
in different disordered regions (IUPred Score >= 0.4) of the proteome. Dileucine motif 
gain is significantly enriched only in disordered regions of the cytoplasmic domains of 
transmembrane proteins (two-sided Fisher’s exact test).  
C, Comparison of gained motifs in disordered regions of cytoplasmic tails of 
transmembrane proteins reveals the dileucine motif to have the most significant specific 
enrichment when compared with polymorphisms. 
D, Antibody feeding indicates that four out of seven tested mutations with gain of 
dileucine motif lead to a gain in endocytosis (candidates from Humsavar and Clinvar for 
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CONTACT FOR REAGENT AND RESOURCE SHARING 
Further information and requests for resources and reagents should be directed to and 
will be fulfilled by the Lead Contact, Matthias Selbach (matthias.selbach@mdc-
berlin.de). 
EXPERIMENTAL MODEL AND SUBJECT DETAILS 
Cell lines 
SH-SY5Y and T-REx™-293 cells were cultured under standard cell culture conditions. 
In brief, cells were cultured in DMEM (Life Technologies) complemented with 10% fetal 
calf serum (Pan-Biotech). 
Cells used for SILAC based experiments were cultured in SILAC DMEM (Life 
Technologies) complemented with glutamine (Glutamax, Life Technologies), Pyruvate 
(Life Technologies), non-essential amino acids (Life Technologies) and 10% dialyzed 
fetal calf serum (Pan-Biotech). The SILAC DMEM was supplemented with standard L-
arginine (Arg0, Sigma-Aldrich) and L-lysine (Lys0, Sigma-Aldrich) (“light”) as in 
(Schwanhäusser et al., 2011). Alternatively, Arg6 and Lys4 (“medium-heavy”) or Arg10 
and Lys8 (“heavy”) were added in place of their light counterparts. Cells were cultured 
at 37 °C and 5% CO2. 
Flp-In T-Rex GLUT1 
We purchased SLC2A1 (GLUT1) from Harvard Plasmid repository (HsCD00378964). A 
stop codon has been added to the gene with the following primers 
Fw:TCCCAAGTGTAATTGCCAACTTTCTTGTACAAAGTTG, 
Rev:ATCAGCCCCCAGGGGATG. 
P485L Mutation has been introduced by changing c.1454 C>T (Slaughter et al., 2009) 
with Q5® Site-Directed Mutagenesis Kit (NEB) Fw:CTGTTCCATCtCCTGGGGGCT, 
Rev:CTCCTCGGGTGTCTTGTCAC. 
SLC2A1 and SLC2A1 mutant have been further cloned into a destination vector with a 
N-terminal BirA-FLAG Tag (pDEST-pcDNA5-BirA-FLAG N-term (Couzens et al., 2013))
with Gateway cloning strategy (Thermo Fisher Scientific). HEK293 Flp-In T-Rex cells 
(Invitrogen) that exhibit tetracycline-inducible expression of BirA-FLAG-GLUT1 or BirA-
FLAG-GLUT1_P485L were generated using the Flp-In system developed by Life 
Technologies according to the manufacturer’s protocol. 
Patient-derived iPSCs 
Fibroblasts were obtained from a GLUT1 deficient patient with the P485L mutation. The 
voluntary informed consent process was documented in writing as approved in advance 
by the University of Texas Southwestern Medical Center Institutional Review Board. 
This included information regarding the de-identification of the sample and the 
adherence to HIPAA regulations. 
A 4 mm single-use, sterile skin punch was applied to the lateral surface of the left 
shoulder after the skin had been cleansed with iodine solution in aseptic fashion 
followed by injection of 0.5 mL of 1% unbuffered lidocaine with a vasoconstrictor. 
Prilocaine and lidocaine cream had been previously applied to the area. The punch was 
advanced by rotation under pressure and the explant was severed from its base and 
harvested in culture medium containing complete DMEM plus 20% fetal bovine serum 
and placed on ice until the explant was divided for culture the same day. The explant 
was divided into 12-15 evenly sized pieces and each piece maintained in a 10 cm dish 
at 37 °C until fibroblast confluence was reached. The cells were then treated with 
trypsin and passaged into a T-25 flask for further expansion. Fibroblasts were grown to 
approximately 50% confluence in the T-25 flask. They were then suspended with trypsin 
and frozen over dry ice in complete DMEM medium with 10% DMSO at a density of 106 
cells/ml per vial prior to storage and shipment on dry ice.  
The patient fibroblast were reprogrammed using the mRNA reprogramming kit 
ReproRNA™-OKSGM from Stem Cell Technologies according to the instructions. In 
brief, 1x 105 fibroblast cells were plated on Geltrex coated 6-well plate using regular 
DMEM media with 10% FBS. The day after the cells were transfected with the 
ReproRNA- OKSGM construct using the ReproRNA transfection reagents and growth 
Media with B18R. The next 5 days the growth media was changed every day and 
supplemented with B18R and 0.8 µg/ml Puromycin. After 8 days the growth media was 
exchanged by ReproTeSR and first colonies appeared after 14 days. In total 5 clones 
were picked and established using mTESR-1 media. As a control for the experiments 
the following fibroblasts (NHDF-Ad-Der Fibroblasts, C-2511, LONZA) were 
reprogrammed using the Epi5™ Episomal iPSC Reprogramming Kit from Thermo 
Fisher Scientific following the vendor's instructions. The established lines and clones 
were registered and named using the Human pluripotent stem cell registry 
(https://hpscreg.eu/): BIHi037-(A-E). 
The iPSCs used for the experiments were characterized using the PSC 4-Marker 
immunocytochemistry kit from Thermo Fisher Scientific following the instructions of the 
protocol. In addition to the 4 markers (OCT4, SOX2, TRA-1-60 and SSEA4) included in 
the kit, the expression of another pluripotency marker NANOG (Nanog PA1-097, 
Thermo Fisher Scientific) was analyzed.  
Human iPSC cultures were maintained on plates coated with hESC-Qualified Matrigel™ 
(Corning) in mTESR-1 medium (Stem Cell Technologies) following the manufacturer's 
instruction. All cells were cultured at 37 °C in humidified atmosphere containing 5% O2 
and 5% CO2. Cells were passaged using StemPro Accutase (Thermo Fisher) and 
replated in mTESR 1 medium w ith the addition of 10 μ  R CK inhibitor -27632 (LC 
Laboratories). 
Animal model
Glut P485 mice were produced by microinjection of C57BL/6N zygotes with Cas9 
protein (IDT), synthetic guide RNA (IDT) (5’GAGGAGCTCTTCCACCCTCT3’) and a 
mutagenic single stranded deoxyoligonucleotide (IDT) 
(5’TAGCTGCCTGTGCTCCAGAGAGATCCTTGGGCTGCAGGGAGCAGGCCGGGCT
GGGTGTGGGGCTCCTCACACTTGGGAGTCCGCCCCCAacaaGTGGAAGAGCTCCT
CGGGTGTCTTGTCACTTTGG3’) as recombination template, as described (Wefers et 
al., 2017) . Reagents were diluted in microinjection buffer (10 mM Tris, 0.1 mM EDTA, 
pH 7.2), filtrated through a centrifugal filter (Millipore, UFC30LG25) and stored in single 
use aliquots at -80°C.  For microinjections, zygotes were obtained by mating of 
C57BL/6N males with superovulated C57BL/6N females (Charles River, Sulzbach, 
Germany). Zygotes were injected into one pronucleus following standard procedures 
(Ittner and Götz, 2007). Injected zygotes were transferred into pseudo-pregnant NMRI 
female mice to obtain live pups. All mice showed normal development and appeared 
healthy. Mice were handled according to institutional guidelines under experimentation 
license no. G0162/12 approved by the Landesamt für Gesundheit und Soziales (Berlin, 
Germany) and housed in standard cages in a specific pathogen-free facility on a 12 h 
light/dark cycle with ad libitum access to food and water. 
METHOD DETAILS 
Peptide-protein interaction screen 
Candidate selection 
Disease mutations in humans were taken from UniProt annotations (UniProt 
Consortium, 2012) of Online Mendelian Inheritance in Man, OMIM®. McKusick-Nathans 
Institute of Genetic Medicine, Johns Hopkins University (Baltimore, MD), 
https://omim.org/. This dataset consists of experimentally validated missense mutations 
that contribute to inherited diseases. Inherited disease mutations were downloaded from 
UniProt (http://www.uniprot.org/docs/humsavar.txt,  Release: 2015_07 of 24-Jun-2015, 
(Famiglietti et al., 2014)). Only mutations that were associated to ‘Disease’ were kept. 
‘Unclassified’ mutations or ‘Polymorphisms’ were excluded. The 26,649 disease 
mutations were further filtered by applying a disorder cut-off. Disorder tendencies of 15 
amino acids (AAs) long peptides, with the AA mutated in disease if possible located at 
position eight, were predicted using IUPred (Dosztányi et al., 2005) using the ‘SHORT’ 
profile considering sequential neighbourhood of 25 residues. IUPred disorder scores 
above 0.5 denote regions of the proteins that have 95% likelihood to be disordered. For 
filtering, the mean disorder score for all 15 AA as well as the mutation position were 
required to be >0.5. This resulted in 1,878 disease mutations in disordered regions. 
Next we assigned disease classes to 3,119 different diseases included in the humsavar 
database by combining a manual approach with automatic annotation with the Human 
Phenotype Ontology database, HPO (Köhler et al., 2017). We selected 305 mutations 
causing neurological diseases. After manual inspection, we remained with 128 
mutations causing 124 distinct neurological diseases that were used for the peptide-
protein interaction screen. 
Experimental setup 
Peptides of 15 AAs, in total 128 wild-type peptide and 128 related peptides containing 
the disease causing mutation (256 peptides) plus one control peptide pair were 
synthesized in situ on cellulose membrane using PepTrack™ techniques (JPT Peptide 
Technologies, Berlin, Germany). Two of those peptide filters were moistened in cell lysis 
buffer [50 mM HEPES pH 7.6 at 4 °C, 150 mM  NaCl, 1 mM EGTA, 1 mM MgCl2, 10% 
Glycerol, 0.5% Nonidet P-40, 0.05% SDS and 0.25% sodium deoxycholate, 
supplemented with protease inhibitor (Roche) and benzonase (Merck)]. In order to 
reduce nonspecific binding, the membrane was incubated with 1 mg/ml yeast t-RNA 
(Invitrogen) for 10 min and then washed twice with cell lysis buffer. The entire peptide 
libraries were incubated with 15 ml of light or heavy SILAC labeled cell lysate (5 mg/ml) 
from SH-SY5Y cells for 2 h. Membranes were washed three times and air dried. 
Sample preparation for mass spectrometric analysis 
Single spots were punched out from cellulose membrane with a 2 mm diameter ear 
punch (Carl Roth) and SILAC pairs were placed together in a 96-well plate (Thermo 
Fisher Scientific) prepared with 30 µl of denaturation buffer [6 M urea (Sigma-Aldrich), 
2 M thiourea (Sigma-Aldrich), 10 mM HEPES, pH 8]. Samples were reduced by 
incubating with 10 µl of 3.3 mM DTT (Sigma-Aldrich) for 30 min at RT, followed by an 
alkylation step using 10 µl of 18.3 mM iodoacetamide (IAA) (Sigma-Aldrich) for 60 min 
at RT. The samples were first digested using 1 µg endopeptidase LysC (Wako, Osaka, 
Japan) for 4 h. The samples were diluted by adding 100 µl of 50 mM ammonium 
bicarbonate (pH = 8.5), and finally digested with 1 µg trypsin (Promega) for 16 h. The 
digestion was stopped by acidifying each sample to pH < 2.5 by adding 10% 
trifluoroacetic acid solution. The peptide extracts were purified and stored on stage tips 
according to (Rappsilber et al., 2003). 
LC-MS/MS analysis 
Peptides were eluted using Buffer B (80% Acetonitrile and 0.1% formic acid) and 
organic solvent was evaporated using a speedvac (Eppendorf). Samples were diluted in 
Buffer A (5% acetonitrile and 0.1% formic acid). Peptides were separated on a 
reversed-phase column with 45 min gradient with a 250 nl/min flow rate of increasing 
Buffer B concentration on a High Performance Liquid Chromatography (HPLC) system 
(Thermo Fisher Scientific). Peptides were ionized using an electrospray ionization (ESI) 
source (Thermo Fisher Scientific) and analyzed on a Q-exactive plus Orbitrap 
instrument (Thermo FisherScientific). Dynamic exclusion for selected precursor ions 
was 30 s. The mass spectrometer was run in data dependent mode selecting the top 10 
most intense ions in the MS full scans, selecting ions from 300 to 1700 m/z (Orbitrap 
resolution: 70,000; target value: 1,000,000 ions; maximum injection time of 120 ms). 
The resulting MS/MS spectra from the Orbitrap had a resolution of 17,500 after a 
maximum ion collection time of 60 ms with a target of reaching 100,000 ions. 
Data analysis 
The resulting raw files were analyzed using MaxQuant software version 1.5.2.8 (Cox 
and Mann, 2008). Default settings were kept except that ‘match between runs’ and ‘re-
quantify’ was turned on. Lys8 and Arg10 were set as labels and oxidation of 
methionines and N-terminal acetylation were defined as variable modifications. 
Carbamidomethyl of cysteines was set as fixed modification. The in silico digests of the 
human Uniprot database (2015-12), a FASTA file containing all peptides used for pull-
down and a database containing common contaminants were done with Trypsin/P. The 
false discovery rate was set to 1% at both the peptide and protein level and was 
assessed by in parallel searching a database containing the reversed sequences from 
the Uniprot database. Following statistics and figures were done using R (R version 
3.2.1, RStudio Version 1.0.143). The resulting text files were filtered to exclude reverse 
database hits, potential contaminants, and proteins only identified by site. We imputed 
missing LFQ-intensity values with random noise simulating the detection limit of the 
mass spectrometer (Keilhauer et al., 2015). To this end, imputed values are taken from 
a log normal distribution with 0.25× the standard deviation of the measured, 
logarithmized values, down-shifted by 1.8 standard deviations. In this way, we obtained 
a distribution of quantitative values for each protein across samples. For determination 
of specific interactions, two replicated pull-downs for the same peptide were tested 
against all other pull-downs, excluding the corresponding variant peptide, by the 
nonparametric Mann–Whitney U test. Resulting p-values and fold-changes (log2 space) 
have been plotted as volcano plots to determine cut-offs. We used an approach that 
uses a graphical formula to combination a fold-change and p-value cut-off (Keilhauer et 
al., 2015): −𝑙𝑙𝑙𝑙𝑙𝑙10(𝑝𝑝)  ≥ 𝑐𝑐|𝑥𝑥|−𝑥𝑥0with x: enrichment factor of a protein, p: p-value of the 
Mann–Whitney U test calculated from replicates, x0: fixed minimum enrichment, c: 
curvature parameter. The curvature parameter c determines the maximum acceptable 
p-value for a given enrichment x.
The parameters c and x0 can be optimized based on prior knowledge of known true and
false positives (Keilhauer et al., 2015). Here, cut-offs were chosen according to known
interaction partners of the SOS1 control peptide (Keilhauer et al., 2015; Schulze and
Mann, 2003). This resulted in x0=0, c=8.
This cut-off was applied to all other pull-downs to separate specific binders from
background. SILAC ratios were normalized by subtracting the median SILAC ratio of
every experiment from all SILAC ratios in that experiment. To define interaction partners
that bind differentially to wild-type and mutant peptide, a SILAC cut-off has been
defined. For wild-type specific interaction partners, the mean log2 SILAC ratio of the two
replicates needed to be >1 and none of the two ratios <0 (mutant specific mean log2




Peptides were separated by reverse phase chromatography on an effective 150 min 
gradient (0, 2, 100, 30, 15, 1 and 5 min with 2, 4, 20, 30, 60, 90 and 90 % of buffer B 
with 90 % acetonitrile) and analyzed on a Q-Exactive HFx (Thermo Fisher Scientific). 
The PRM settings were: 30,000 resolution; 5e5 AGC target; 1.6 m/z isolation window; 
60 ms max ion injection time. The inclusion list for the PRM method was generated 
using Picky (Zauber et al., 2018) with SILAC option enabled and a retention time 
window of 30 min. Predicted retention-times were calibrated in Picky with a complex 
sample of 100 ng Pierce HeLa Protein standard (Thermo Fisher Scientific) immediately 
before the PRM measurements. 
Analysis of PRM data 
Traces of all fragments from precursors in the spectral library (as exported from picky) 
were extracted from all rawfiles using the Thermo MSFileReader and the 
MSFileReader.py bindings written by François Allen. For each light or heavy scan the 
normalized spectral contrast angle (SCN) was calculated (Toprak et al., 2014). Peaks 
were manually selected and required a SCN > 0.4 and Fragment Matches > 4 in the 
light or heavy channel. Further Peaks needed to be within a similar retention time range 
across all different measurements. Ratios for each fragment using the maximum 
intensity of each peak were calculated. The median log2 transformed ratio (log2FC) for 
each peptide in each raw-file was calculated from selected fragment ratios: The five 
highest abundant fragments were selected from the peak with the highest detected 
SCN. Peptide log2FC were plotted as boxplot distributions in a protein centric manner 
across the different experiments (Fig. S4A). 
BioID 
Medium-heavy and heavy labelled T-REx™-293 cells have been induced for 24 h with 
0.1 µg/ml Doxycycline to induce expression of GLUT1 (wild-type, wt) or GLUT1_P485L 
(mutant, mut). Light labelled cell lines from both GLUT1 and GLUT1_P485L have been 
left uninduced and served as a control for background binding. SILAC labeling allowed 
for quantitative comparison of proteins that have been proximity labelled by the 
transiently expressed constructs (Forward experiment: Light - Control, Medium-heavy - 
wt, Heavy - mut; Label swap experiment:  Light - Control, Medium-heavy - mut, Heavy - 
wt). During the induction period all cell lines have been incubated for 24 h in cell culture 
medium containing biotin. BioID experiment has been performed essentially as in 
(Couzens et al., 2013), with minor adaptations. 
Mass spec setup and analysis was done similarly as to samples from peptide pull-
downs, but on bead digested peptides were separated on a 2,000 mm monolithic 
column with a 100 µm inner diameter filled with C18 material that was kindly provided 
by Yasushi Ishihama (Kyoto University) using a 4 h linear gradient with a 300 nl/min 
flow rate of increasing Buffer B concentration on a High Performance Liquid 
Chromatography (HPLC) system (Thermo Fisher Scientific). The resulting raw files were 
analyzed using MaxQuant software version 1.5.2.8 (Cox and Mann, 2008). Default 
settings were kept except that ‘match between runs’ and ‘re-quantify’ was turned on. 
Lys4 and Arg6 or Lys8 and Arg10 were set as labels and oxidation of methionines and 
n-terminal acetylation were defined as variable modifications. Carbamidomethyl of
cysteines was set as fixed modification. The in silico digests of the human Uniprot
database (2015-12), a fasta file containing the sequence of BirA-FLAG-GLUT1 and a
database containing common contaminants were done with Trypsin/P. The false
discovery rate was set to 1% at both the peptide and protein level and was assessed by
in parallel searching a database containing the reversed sequences from the Uniprot
database.
Biotinylated proteins with a wild-type to mutant enrichment ratio (log2FC) >1 or <-1 have
been considered as significant. These proteins have been analysed for gene ontology
enrichment of cellular components with http://metascape.org (Tripathi et al., 2015).
FLAG-GLUT1 localization 
HEK293 Flp-In T-Rex cells with BirA-FLAG-GLUT1 or BirA-FLAG-GLUT1_P485L have 
been seeded on coverslips coated with poly-l-lysine (Sigma-Aldrich). After induction for 
24 h in doxycycline (0.1 µg/ml) containing media, cells were fixed with 4% PFA 
(paraformaldehyde). Standard procedures were used for immunostaining. Cells have 
been stained against FLAG 1:200 (F1804, Sigma-Aldrich). Nucleus has been stained 
with DAPI (Sigma-Aldrich). FLAG staining was accompanied by staining to one of the 
following endosomal markers and with the following dilutions: anti-EEA1 (Cell Signaling 
Technology, 1:100); anti-Rab4 (Cell Signaling Technology, 1:100); anti-Rab9 (Cell 
Signaling Technology, 1:100); anti-LAMP1 (Cell Signaling Technology, 1:100). Mouse 
anti-FLAG staining was substituted by rabbit anti-GLUT1 (Merck Millipore, 1:500) to 
costain mouse monoclonal antibodies: anti-VTI1A (BD Biosciences, 1:100); anti-VTI1B 
(BD Biosciences, 1:100). Secondary antibodies all come from Invitrogen. For 
colocalization analysis three z-stacks of 5-10 cells each have been quantified for each 
marker with Imaris v8.4.1 (see “Quantification and statistical analysis” for details). 
Transferrin uptake 
Essentially as in “FLAG-GLUT1 localization”. Additionally, after 24 h cells were serum-
starved for 1 h and used for Transferrin (Tf) uptake. For Tf uptake, cells were treated 
with 10 μg ml 1 Tf-Ale a  ( ife Technologies) for 10 min at 3 C. or colocalization 
analysis three z-stacks of more than 15 cells each have been quantified with Imaris 
v8.4.1 (see “Quantification and statistical analysis” for details). 
FLAG-GLUT1 localization under AP-2 µ knock-down 
To rescue the GLUT1_P485L phenotype, clathrin mediated endocytosis (CME) has 
been inhibited by knocking down AP-2 µ and hence the adaptor complex responsible for 
recognition of cargo for CME. 
On day 1, cells were seeded in 6-well plates. On day 2, cells were transfected with 
25 nM final siRNA concentration (AP-2 µ: ON-TARGETplus Human AP2M1 
(Dharmacon) and non-target: ON-TARGETplus Non-targeting Pool (Dharmacon)) 
according to DharmaFECT (Dharmacon) transfection protocol. 24 h after the 
transfection, medium was replaced with complete medium to reduce cytotoxicity and 
incubated for another 24 h. On day 4, siRNA transfection was repeated as described for 
day 2. On day 5, cells have been seeded in a 24-well plate onto coverslips coated with 
poly-L-lysine (Sigma-Aldrich) for microscopy and into a 6-well plate for western blot 
analysis. Doxycycline (0.1 µg/ml) has been added to the medium to induce expression 
of the GLUT1 constructs. After induction for 48 h, cells in 24-well plates were fixed with 
4% PFA. Standard procedures were used for immunostaining. Cells were stained with 
rabbit polyclonal GLUT-1 antibody 1:200 (Merck Millipore) and co-stained with mouse 
monoclonal anti-alpha adaptin antibody [AP6] 1:200 (Abcam). Secondary antibodies 
with Alexa fluorophores have all been purchased from Invitrogen. Nucleus has been 
stained with DAPI (Sigma-Aldrich). 
Lysate from cells in 6-well plates has been used for western blotting, α and μ2 subunits 
of AP-2 were detected using mouse monoclonal antibodies from Thermo Fisher 
Scientific and BD transduction, respectively. Profilin 1 was stained as a loading control 
with polyclonal rabbit antibody from CST. Horseradish peroxidase coupled secondary 
antibodies were purchased from GE Healthcare. Proteins were detected with  
chemiluminescence substrate (Perkin Elmer) on a ChemiDoc MP Imaging System (Bio-
Rad) and quantified with Image Lab 5.2.1. 
Antibody feeding assay 
An antibody feeding assay was used to study the gain of endocytosis by gain of 
dileucine motifs. For antibody internalization assay, genes and cytoplasmic regions 
were chosen according to the following criteria: All 11 disease mutations from 
Humsavar and Clinvar (‘Pathogenic’ or ‘Conflicting interpretations of pathogenicity’, in 
case ‘pathogenic’ or likely pathogenic was included in the different interpretations) that 
lead to a gain of a dileucine motif have been considered. All regions +/-7 AAs of the 
mutation have been analysed according to Eukaryotic Linear Motif (ELM) database 
(Dinkel et al., 2016). CACNA1H_P618L and RET_P1039L were not considered for the 
assay since wild-type variants of the peptides already harbour trafficking motifs. For 
GLUT1_P485L the whole cytoplasmic C-terminus was amplified via PCR adding EcoRV 
5’ and NotI 3’. All other seven constructs were generated by inserting the region 
surrounding the mutation position with Q5® Site-Directed Mutagenesis Kit (NEB) 
resulting in a 15 AA insert (we were not able to generate a construct for 
CACNA1H_P648L). Chimeras consisting of one of the cytoplasmic regions and the 
human TAC antigen (interleukin-2 receptor α chain, CD2 ) were constructed based on a 
TAC construct (Diril et al., 2009). HeLa cells were transiently transfected with the TAC 
chimera constructs using jetPRIME (Polyplus-transfection). Two days after transfection, 
cells were labelled with anti-TAC IgG (Santa Cruz Biotechnology) (1 : 1000 diluted in 
Opti-MEM; Invitrogen) for 30 min at 4 °C. After one change of medium (to Opti-MEM at 
37 °C), plasma membrane antigens were allowed to internalize for 30 min at 37 °C. The 
cells were then fixed with 4% paraformaldehyde (Sigma-Aldrich) for 10 min on ice, and 
surface-bound TAC antibody was blocked using goat anti-mouse serum [goat anti-
mouse IgG (Thermo Fisher Scientific at a 1 : 5 dilution in goat serum dilution buffer, 
consisting of 30% normal goat serum (Sigma-Aldrich), 450 mm NaCl in 20mM sodium 
phosphate buffer  pH 7.4] for 2 h at room temperature. Cells were permeabilized and 
blocked with goat serum dilution buffer containing 0.2% saponin for 10 min. For 
detection of internalized TAC antibody, a goat anti-mouse Alexa Fluor 488-conjugated 
IgG (Invitrogen) was added for 1 h. Cells were then washed three times for 10 min each 
with sodium phosphate buffer containing 0.02% saponin. For total TAC staining, the 
specimens were incubated for 1 h with TAC antibody diluted 1 : 1000. As secondary 
antibody, an Alexa Fluor 594-conjugated goat anti-mouse IgG (Invitrogen) was added 
for 30 min, and nuclei were stained using DAPI (Sigma-Aldrich). Cells were washed, 
and coverslips were mounted in ProLong® Gold antifade reagent (Invitrogen). For 
imaging, cells with positive signal in the 594 channel were chosen. All cells in Fig. 7 D 
are positive for total TAC staining (594). We have seen that the level of internalised 
TAC chimera (488) does not correlate with the amount of total TAC staining (594), 
between samples and in the same sample, and hence we have decided to exclude this 
channel from visualization. 
GLUT1 localization in iPSCs 
Human iPSCs were seeded on coverslips coated with hESC-Qualified Matrigel™ 
(Corning). Cells were fixed with 4% PFA, stained with rabbit polyclonal GLUT1 antibody 
1:200 (Merck Millipore) and costained with mouse monoclonal VTI1a antibody 1:100 
(BD Biosciences). Secondary antibodies with Alexa fluorophores have all been 
purchased from Invitrogen. 
Fluorescence microscopy from cell culture 
Images from FLAG-GLUT1 localization were acquired by Leica DMI6600 confocal laser 
scanning microscope with an HCX PL APO 63.0/1.40 oil objective. Transferrin uptake, 
GLUT1-localisation under AP-2 µ knock down, antibody feeding assay and GLUT1 in 
iPSCs were acquired by a Zeiss LSM 700 confocal laser scanning microscope with an 
EC Plan-Neofluar/NA1.3 40x oil objective or a EC Plan-Apochromat/NA1.4 63x oil 
objective. Images were further processed with Fiji (Schindelin et al., 2012). For 
colocalization analysis see “Quantification and statistical analysis”.  
Immunofluorescence in mouse tissue 
E14-E15.5 embryos were obtained by Caesarian section from pregnant dam on day 14-
15.5 post-coitus. Whole-mount embryos were dissected in ice-cold phosphate buffer 
and fixed for 2 h with a solution of 4% PFA in ice-cold phosphate buffer and 
cryoprotected overnight in 30% sucrose in phosphate buffer at 4°C. Whole embryo 
heads were sectioned in a horizontal plane using a cryostat to obtain 12-1 μm sections.  
Sample preparation for confocal microscopy 
Essentially as in (Hernández-Miranda et al., 2011). Brain  sections were incubated in 
blocking buffer 1 (5% horse serum and 0.1% Triton™-X 100 made in phosphate buffer) 
for 1 h at room temperature. Then, sections were incubated overnight in blocking buffer 
1 containing the following antibodies: rabbit anti-Glut1 (1:200; Merck Millipore #07-
1401), rat anti-ICAM2 (1:100; BD Biosciences #553326) and Isolectin GS-IB4 Alexa 
Fluor 488 conjugate (1:100, Thermo Fisher Scientific #I21411) at 4°C. Next, sections 
were washed three times in ice-cold phosphate buffer and incubated for 3 h in blocking 
buffer 1 containing Cy3 horse anti-rabbit (1:500; Jackson Lab), Cy5 horse anti-rat 
(1:500; Jackson Lab) and DAPI at room temperature. Fluorescence was imaged on a 
Zeiss LSM 700 (Jena, Germany) confocal microscope in a non-blind manner. 
Sample preparation for STED microscopy 
Sections were washed twice for 5 minutes with PBS to remove the embedding resin and 
incubated in 0.2% Triton X-100 in blocking buffer 2 (1% bovine serum albumin, 1% fetal 
calf serum in PBS) for 1 hr at room temperature. Samples were incubated with primary 
antibodies anti-Glut1 (rabbit anti-human, Merck Millipore #07-1401) and anti-ICAM2 (rat 
anti-mouse CD102, BD Biosciences #553326) at 1:100 dilution in blocking buffer 2 
overnight at 4°C. Next, samples were washed three times for 5 minutes in PBS and 
incubated with STAR Red goat anti-rabbit antibody (Abberior, #2-0012-011-9), Alexa 
Fluor 594 donkey anti-rat antibody (Thermo Fisher Scientific #A21209), and Isolectin 
GS-IB4 Alexa Fluor 488 conjugate (Thermo Fisher Scientific #I21411), all diluted at 
1:500 in blocking buffer 2. Subsequently, samples were washed three times for 5 
minutes in PBS and mounted in Abberior Mount Solid Antifade mounting reagent 
(Abberior, #4-0100-007-4) under #1.5 coverslips (22x50 mm, VWR #631-0138) and 
allowed to cure overnight at room temperature. 
STED imaging and image analysis 
IB4 and ICAM2 signals were used to assess the positions of luminal (IB4 and ICAM2 
positive) and abluminal (IB4 positive, ICAM2 negative) vessel membranes. Cross-
sections of vessels (10-20 per animal) were selected for imaging in areas where luminal 
and abluminal membranes were clearly distinguishable, typically in the vicinity of the 
endothelial cell nucleus. 
STED images were acquired using Abberior STED microscope equipped with 640 nm, 
561 nm and 485 nm pulsed excitation lasers, 775 nm and 595 nm pulsed depletion 
lasers, UPlanSApo 100x/1.40 Oil objective (Olympus), 509/22 (GFP), 605/50 (Cy3) and 
685/70 (Cy5) bandpass emission filters and spatial light modulators for STED beam 
shaping and alignment. Emitted light was collected with avalanche photodiode detectors 
using 8 ns-wide detection time gates. 120 µs total pixel dwell time per channel was 
used. Cy3 and Cy5 channels were acquired by line switching followed by the acquisition 
of the GFP channel.  
STED images in 488 nm and 640 nm channels were aligned using reference images of 
fluorescent beads (Tetraspeck, 100 nm, ThermoFisher Scientific #T7280). Centers of 
beads were determined by centroid fit and resulting positions were used as control 
points to calculate an affine transformation between the 488 nm and 640 nm channels.  
To quantify the average amount of membrane-localized Glut1 per vessel, a 
measurement area containing all pixels within 300 nm of manually segmented abluminal 
membrane was created. Luminal membranes were not included in the analysis due to 
frequent collapse of vessels during sample preparation. The ratio between mean Glut1 
and mean IB4 signal was used as a measure of Glut1 to account for the amount of 
membrane in the measurement area, imaging depth and antibody penetration 
differences between samples. The ratio of Glut1 to IB4 was further corrected using 
images of Tetraspeck beads for relative intensity fluctuations between Cy5 and GFP 
detection channels between imaging sessions. Statistical significance was assessed 
using unpaired Student’s t-tests of log2 transformed data. The analysis was performed 
using ImageJ and Matlab 2015 (Mathworks, Inc). 
Radioactive glucose uptake under AP-2 µ knock-down 
AP-2 knock down has been performed as described before (FLAG-GLUT1 localization 
under AP-2 µ knock-down). Only that cells have been seeded in triplicates in a 24-well 
plate without coverslips. Radioactive glucose uptake was performed mainly as in (Shi 
and Kandror, 2008).  Radioactive glucose coc tail was prepared b  adding 10 μ  of 3H-
2-deoxy-D-glucose in ethanol:water solution (specific activity, 5–10 Ci (185–370 GBq) / 
mmol) (Perkin Elmer) to a 2.0-mL tube and left open for 5 min to evaporate ethanol. 1.6 
m  of KRH( ) glucose and 1  μ  of cold 2-DOG (100X) stock solution (100 mM 2-
deoxy-D-glucose in KRH ( ) glucose) (Sigma-Aldrich) were added to the tube. Cells in 
each well were rinsed with DMEM (without serum, SFM) warmed to 37°C and SFM was 
added to cells slowly and carefully by the side of the well in order to avoid detachment 
of cells. Cells were incubated with 0.5 mL of SFM (in case of +dox containing 1µg/µl 
doxycycline) per well for 2 h at 37°C. Cells in each well were washed twice with 2 mL of 
KRH( ) glucose buffer (121 m  NaCl, .  m  KCl, 1.2 m  gS , 0.33 m  CaCl2, 
12 mM HEPES, pH 7.4) at 37°C. 225µl of KRH(-) containing 25 µM final Cytochalasin B 
(dissolved in D S ) or 0.  D S  were added to each well. Immediatel  after, 2  μ  
of radioactive glucose cocktail was added to all wells. Samples were incubated at 37°C 
for 1 h and then transferred on ice. Radioactive glucose cocktail was aspirated, and ice-
cold KRH (+) glucose (121 mM NaCl, 4.9 mM KCl, 1.2 mM MgSO4 0.33 mM CaCl2:12 
mM HEPES, 25 mM D- (+)- Glucose, pH 7.4.) was added to terminate the reaction. 
Cells were washed once more with ice-cold KRH(+) glucose. Plate was transferred to 
room temperature, and 00 μ  of 0.1  SDS in KRH ( ) glucose have been added to 
each well, incubated at room temperature for 10 min, and thoroughly resuspend to 
homogeneity. 100 µl of the lysate was kept to measure protein concentration with DC 
protein assay kit I ( ioRad). 300 μ  of l sates have been transferred in scintillation vials 
containing 4 mL of Rotiszint eco plus scintillation fluid (Carl Roth) and count in a Liquid 
Scintillation Analyzer (Tri-Carb 2800TR, PerkinElmer) for 1 min per vial. These numbers 
represent Counts in the samples . In parallel, 10 μ  of the radioactive glucose coc tail 
have been mi ed with 2 0 μ  of 0.1  SDS in KRH ( ) glucose and this mi ture was 
measured under the same conditions. This number represents “Counts in the cocktail”. 
The amount of intracellular 2-deoxyglucose was calculated using the following formula: 
� [𝐶𝐶𝑙𝑙𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶 𝑖𝑖𝐶𝐶 𝐶𝐶ℎ𝑒𝑒 𝐶𝐶𝑠𝑠𝑠𝑠𝑝𝑝𝑙𝑙𝑒𝑒]×1000[𝐶𝐶𝑙𝑙𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶 𝑖𝑖𝐶𝐶 𝐶𝐶ℎ𝑒𝑒 𝑐𝑐𝑙𝑙𝑐𝑐𝑐𝑐𝐶𝐶𝑠𝑠𝑖𝑖𝑙𝑙]×0.03×[𝐶𝐶]×𝐶𝐶�pmol/mg×min, where [C] is protein concentration in mg/ml 
and t is the total time of incubation with radioactive glucose in min. All resulting values 
have been divided by the overall mean value from all wild-type GLUT1 (+ doxycycline, - 
cytochalasin B) and multiplied by 100 to receive relative values for glucose uptake (%). 
For test of statistical significance, the mean values of three technical replicates were 
calculated from three biological replicates. Values labeled with an asterisk were tested 
for statistical significance in a paired, one-tailed t-test. Depicted values are mean values 
over all replicates and error bars show standard error of mean (SEM) over all replicates. 
GST pulldown assay 
GLUT1 cytoplasmic c-terminal tail has been amplified from 
pDEST_pcDNA5_FLAG_BirA GLUT1 or GLUT1P485L with Fw: 
tatatcGAATTCGTTCCTGAGACTAAAGGC, Rev: 
aacaatGCGGCCGCTTACACTTGGGAATCAGCC. This resulted in C-terminal tail amino 
acids 451-492 (UniProt P11166). Added EcoRI and NotI restriction sites have been 
used to insert the PCR product into pGEX6P1. 
Other cytoplasmic regions have been ordered as gBlocks Gene Fragments (IDT) from 
the region +/- 20AA of the mutation position, with an additional 5’- EcoRV restriction site 
and 3’- Stop codon - NotI restriction site. After restriction, the gene fragments have been 
inserted into pGEX6P2.   
Expression of GST-tagged proteins was induced for 5 h at 22 °C by addition of isopropyl 
thio- -d-galactoside (0.5 mM) to E.Coli BL21 in 2X YT medium (0.8 OD). To lyse the 
cells, bacterial pellets were resuspended in PBS and left on ice for 15 min in presence 
of PMSF (1mM), c anase ( ) and l soz me (1 mg m 1). Then, Triton -100 was 
added to a 0.5% and cells were sonicated for 2 min. Lysates were centrifuged for 15 
min at 0 000  g. 300 μ  of glutathion-coupled beads were added to the supernatant 
and rotated end-over-end for 2 h at 4 °C. Beads were washed three times with PBS / 
0.1% Triton X-100 and once with PBS. 
Pulldown experiments were performed using mouse brain extracts. Mouse brains were 
homogenized in buffer (20 mM HEPES, 320 mM sucrose, pH 7.5) containing  protease 
inhibitor cocktail (Sigma-Aldrich). The homogenate was centrifuged at 1000 x g for 10 
min and the supernatant was supplemented with 1% Triton X-100, 50 mM KClMgCl2, 
and kept on ice for 10 min with occasional vortexing. The lysate was cleared by 
centrifugation at 17,000 x g for 15 min and at 178,000 x g for 15 min. The supernatant 
was recovered and used at a concentration of 7.5 mg protein/mL. 
The pulldown e periments were performed using  μg of GST fusion proteins and 0.  
mL protein extract by end-over-end rotation for 3 h. The samples were washed four 
times with buffer containing 20 mM Hepes, 50 mM KCl, 2 mM MgCl2, Triton X-100 (1%) 
and once in the same buffer without detergent. Proteins were eluted from the beads 
twice with Laemmli buffer and analysed by Western blotting. The following antibodies 
and dilutions were used: mouse anti-talin 1:1000 (Sigma-Aldrich), mouse anti- 1 
adaptin of AP-1 1: 00 ( D iosciences), mouse anti α-adaptin of AP-2 1:200 (BD 
Biosciences), horseradish peroxidase-conjugated goat anti-mouse 1:2000 or 1:5000 
(Jackson labs). 
 
Analysis of human missense variants and short linear motifs 
(SLiMs) 
SLiM regular expression patterns 
262 annotated SLiM class definitions (regular expression patterns) were downloaded 
from the Eukaryotic Linear Motif (ELM) database (Dinkel et al., 2016). In order to 
analyse dileucine motifs, an additional motif ‘.LL.’ was added to this compilation and 
named ‘LIG_diLeu_1’ in order to conserve the naming convention followed by the ELM 
database.  
Pathogenic and non-pathogenic missense variants 
Humsavar dataset: For the analysis of the missense variants that lead to de novo SLiM 
instances in protein sequences Uniprot Humsavar dataset (version 12-Apr-2017) 
(Famiglietti et al., 2014) was downloaded and filtered for missense variants. Variants 
that are classified as ‘Disease’ or ‘Polymorphism’ in this dataset were selected.  
ClinVar dataset: Clinically relevant genomic variation data annotated in the ClinVar 
database (Landrum et al., 2016) was downloaded from the ftp server 
(ftp.ncbi.nlm.nih.gov/pub/clinvar/tab_delimited/variant_summary.txt.gz) in tab-delimited 
format (latest update on 25th of March, 2017). The downloaded table was filtered for 
assembly version GRCh38, and variants of type ‘single nucleotide variant’ were kept. In 
order to integrate the ClinVar annotations with other kinds of annotations available from 
the Uniprot database, these nucleotide variants were translated to the Uniprot protein 
sequences to obtain single amino-acid substitutions using the Ensembl Variant Effect 
Predictor (version 82) (VEP) (McLaren et al., 2016). The output of VEP tool was filtered 
to only keep missense variants such that the translated amino-acid substitution occurs 
at exactly the same amino-acid at the same position of the Uniprot sequence with the 
same gene name as those of the annotation in the ClinVar dataset (‘Name’ field). Thus, 
98,219 unique single amino-acid substitutions (missense variants) from 4,298 Uniprot 
sequences were obtained. Variants primarily annotated with clinical significance levels 
‘Pathogenic’, ‘Pathogenic/Likely pathogenic’, or ‘Likely pathogenic’ were grouped as 
‘Disease’ variants, while variants annotated with ‘Benign’, ‘Benign/Likely benign’, or 
‘Likely benign’ were grouped into the ‘Polymorphism’ variants. 
Protein domains 
PFAM domain annotations of proteins were downloaded from the PFAM database 
(ftp://ftp.ebi.ac.uk/pub/databases/Pfam//releases/Pfam30.0/proteomes/9606.tsv.gz) 
(Finn et al., 2016).  
SLiM - PFAM associations 
PFAM domains and SLiM classes that are known to interact were downloaded from the 
ELM database (http://elm.eu.org/interactiondomains).  
Analysis of gain of SLiMs via missense variants in disordered regions 
For each reviewed human protein from Uniprot (20191 proteins), the disorder scores of 
each residue were calculated using IUPred (using the ‘short’ setting). Using a IUPred 
disorder score cut-off of 0.4, the missense variants in disordered regions were selected. 
The missense variants that overlap PFAM domains were further filtered out based on 
the PFAM domain annotations found in the protein feature files downloaded from 
Uniprot in GFF format (e.g. the link to the GFF file for GLUT1 is 
http://www.uniprot.org/uniprot/P11166.gff). These protein feature files were also used to 
detect the transmembrane proteins and their cytoplasmic/extracellular regions. The 
missense variants in disordered regions and not overlapping any PFAM domains were 
further classified as variants from 1) the whole proteome, 2) the transmembrane 
proteins (only those that have annotation of at least one cytoplasmic domain or an 
extracellular domain, in total 3836 proteins), 3) the cytoplasmic domains of 
transmembrane proteins, and 4) extracellular domains of transmembrane proteins. For 
each of these classes, the number of disease-causing variants and the number of 
polymorphisms that lead to a gain of SLiMs was counted and a two-sided Fisher’s Exact 
Test was applied to see if there is a statistically significant difference for the likelihood of 
a given class of SLiMs to be gained via disease-causing variant compared to that of 
polymorphisms.  
Peptide-Protein Interaction Network Analysis     
180 peptide-protein interactions that passed the strict LFQ filter and showed significant 
differential SILAC ratios between wild-type and mutant forms of the peptides were used 
to compose a peptide-protein interaction network. The network was visualized using 
Cytoscape 3.5.1 (Shannon et al., 2003). Sub-graphs of the significant interactions were 
generated using R package igraph (version 1.0.1) (Csardi and Nepusz, 2006) (using 
fastgreedy.community function) and visualized using the R packages ggnetwork 
(Briatte, 2016) and ggplot2 (Wilkinson, 2011). Enriched GO terms for each sub-graph 
were calculated using the topGO R package (Alexa and Rahnenfuhrer, 2016).   
DATA AND SOFTWARE AVAILABILITY  
The mass spectrometry proteomics data have been deposited to the ProteomeXchange 
Consortium via the PRIDE (Vizcaíno et al., 2016) partner repository. The accession number for 
the peptide-protein interaction screen dataset is ProteomeXchange: PXD010027. The 
accession number for the PRM dataset is ProteomeXchange: PXD010005. The accession 
number for the BioID dataset on GLUT1 is ProteomeXchange: PXD010061. 
. 
QUANTIFICATION AND STATISTICAL ANALYSIS 
The type of statistical test (e.g., Mann–Whitney U test or t-test) is annotated in the 
Figure legend and/or in the Methods segment specific to the analysis. In addition, 
statistical parameters such as the value of n, mean/median, SEM, SD and significance 
level are reported in the Figures and/or in the Figure Legends. When * are used to 
signify the significance level the key is reported in the respective Figure legend. 
Statistical analyses were generally performed using R as described in Methods and 
Resources for each individual analysis, if not stated differently. 
Colocalization analysis 
Imaris v8.4.1 was used for the quantitative colocalization analysis. The original z-stack 
images were adjusted by adding an adequate mask on the respective red channel to 
subtract background noise (Costes et al., 2004). The threshold for the mask was 
uniformly adjusted in each staining experiment. Automatic thresholding was used to 
define the area where a colocalization would be determined and the statistics was 
calculated for each colocalization channel (Costes et al., 2004). For the images whose 
observed correlation was not statistically significant in comparison to randomized 
images, the colocalization channel was built without additional thresholding on the 
masked dataset. The resulting thresholded Pearson’s coefficients were exported. The 
number of images and cells in the analyses is stated in the respective Method sections. 
KEY RESOURCES TABLE 
REAGENT or RESOURCE SOURCE IDENTIFIER 
Antibodies 
Mouse monoclonal anti-FLAG Sigma-Aldrich Cat# F3165; 
RRID:AB_259529 
Rabbit polyclonal anti-GLUT1 Merck Millipore Cat# 07-1401; 
RRID:AB_1587074 
Rat monoclonal anti-ICAM2 BD Biosciences Cat# 553326; 
RRID:AB_394784 




Mouse monoclonal anti-Vti1a  BD Biosciences Cat# 611220; 
RRID:AB_398752 
Mouse monoclonal anti-Vti1b BD Biosciences Cat# 611405; 
RRID:AB_398927 




Rabbit monoclonal anti-Rab4 Abcam Cat# ab13252; 
RRID:AB_2269374 








Mouse monoclonal anti-gamma Adaptin (AP-1 ) BD Biosciences Cat# 610385; 
RRID:AB_397768 
Mouse monoclonal anti-AP50 (AP-2 µ) BD Biosciences Cat# 611351; 
RRID:AB_398873 




Mouse monoclonal anti-alpha Adaptin (AP-2 α) Abcam Cat# ab2730; 
RRID:AB_303255 




Chemicals, Peptides, and Recombinant Proteins 
 Deoxy-D-glucose, 2-[1,2-3H (N)]-, Specific Activity: 
5-10 Ci (185-370 GBq)/mmol, 250 µCi (9.25 MBq) 
 Perkin Elmer   NET328250UC  
L-arginine-HCl (Arg0) Sigma-Aldrich A6969; CAS: 1119-
34-2   
L-arginine-HCl(13C6) (Arg6) Sigma-Aldrich 643440; CAS: 
201740-91-2 
L-arginine-HCl(13C6,15N4) (Arg10) Sigma-Aldrich 608033; CAS: 
202468-25-5 
L-lysine-HCl (Lys0) Sigma-Aldrich L8662; CAS: 657-27-
2  




L-lysine-HCl(13C6,15N2) (Lys8) Silantes 211604102 
Cytochalasin B Sigma-Aldrich  C2743; CAS: 14930-
96-2  
Deposited Data 
Peptide-protein interaction screen dataset  This paper  PXD010027 
PRM dataset  This paper  PXD010005 
BioID  This paper  PXD010061 
Humsavar http://www.uniprot.org/
docs/humsavar.txt 








latest update on 25th 
of March, 2017 
(Landrum et al., 
2016)  
Experimental Models: Cell Lines 
Flp-In T-Rex GLUT1 This paper N/A 
Flp-In T-Rex GLUT1_P485L This paper N/A 
Human: Patient-derived iPSCs This paper https://hpscreg.eu/: 
BIHi037-(A-E) 
Experimental Models: Organisms/Strains 
Mouse: C57BL/6N: GLUT1_P485L  This paper N/A 
Oligonucleotides 
ON-TARGETplus Human AP2M1 (1173) siRNA - 
SMARTpool 
 Dharmacon Cat# L-008170-00-
0005 
ON-TARGETplus Non-targeting Pool  Dharmacon Cat# 
D-001810-10-05
Primers TAC chimera constructs This paper See TableS6 
Recombinant DNA 
SLC2A1 (GLUT1) Harvard Plasmid 
Repository 
 HsCD00378964 
Software and Algorithms 




(Cox and Mann, 
2008) 
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Fig. S1: Candidate selection for peptide-protein interaction screen. Related to 
Fig. 1. 
Candidates were selected from missense disease mutations in the Humsavar 
database (Uniprot) by selecting mutations in disordered regions that cause 
neurological diseases (see Methods). 
Fig. S2: Related to Fig. 2. 
A, Reproducibility of technical replicates Pearson’s R shows significantly higher 
correlation of technical replicates than correlations between all pull-downs according 
to Welch Two Sample t-test. 
 B, Impact of specificity cut-off (LFQ) and differential cut-off (SILAC) on peptide 
candidates After applying the specificity cut-off (derived from control peptide, see 
Methods) on all interactions, only about half of the 256 (128 variant pairs) peptides 
showed at least one specific binder according to the LFQ-filter (left pie chart, red). 
These 120 peptides relate to 76 peptide pairs with specific interactions of wild-type 
and/or mutant peptide. More than half of all 76 peptide pairs with specific interactors 
show differential interaction between the variants after applying the SILAC cut-off 
(see Methods) (right pie chart, red). 
C, SILAC ratio distributions of detected interactions that can be explained by 
presence of SLiMs in the peptides and PFAM domains in the interaction 
partners Peptide-protein interactions detected in the screen were classified as 
‘gained’ or ‘lost’ according to the following criteria: An interaction is classified as 
‘gained’ if the mutant peptide sequence matches a SLiM pattern that does not match 
the wild-type peptide sequence and the mutant peptide has an interaction partner 
that contains a compatible PFAM domain to bind that SLiM instance. On the other 
hand, an interaction is classified as ‘lost’ if the wild-type peptide sequence matches a 
SLiM pattern that is not matched in the mutant peptide sequence and the wild-type 
peptide has an interaction partner that contains a compatible PFAM domain to bind 
that SLiM instance. Gained and lost interactions are further sub-classified as ‘LFQ 
positive’ and ‘LFQ negative’ depending on whether the peptide-protein interaction 
has an LFQ value that passes a looser version of the LFQ cut-off (i.e. p-value < 0.05 
and log2 fold enrichment > 1. The median SILAC ratio distributions (wild-type versus 
mutant) of each of these four categories of interactions (‘Gained interactions - LFQ 
negative’, ‘Gained interactions - LFQ positive’, ‘Lost interactions - LFQ negative’, and 
‘Lost interactions - LFQ positive’) are compared with the median SILAC ratio 
distributions of all detected interactions from the array using a Wilcoxon-Mann-
Whitney test. Compared to the background distribution of median SILAC ratios (in 
red), the gained interactions that pass the LFQ filter (in green) show a significant 
negative skew while the lost interactions that pass the LFQ filter (in purple) show a 
significant positive skew. 
Fig. S3: Related to Fig. 4. 
Quantification of Fig.4 B is based on these example images for colocalization study 
of GLUT1 wild-type and P485L mutant to markers of endocytic compartments. 
GLUT1 (green), Marker (red), DAPI (blue) 
Fig. S4: Adaptor proteins bind preferentially to mutant variant peptides 
carrying a dileucine. Related to Fig. 5. 
A, A highly sensitive, targeted mass spectrometry technique (parallel reaction 
monitoring, PRM) reveals that adaptor proteins (AP-1, AP-2, AP-3) bind 
preferentially to peptides carrying a dileucine. B, Raw elution profiles of transitions 
from two example peptides from the proteins AP1G1 and AP2A1 for all forward and 
label swap (reverse) experiments. Ratios were calculated based on extracted 
intensity informations from the light and heavy channel in each experiment for each 
transition. Different transitions are displayed with different colors. The spectrum 
contrast angle (SCA) indicates similarity to the corresponding spectrum in the 
spectrum library and is displayed for every peak.  
Fig. S5: iPSCs show pluripotency markers. Related to Fig. 6.  
iPSCs (BIHi037-A) were reprogrammed from a G1DS patient carrying a 
heterozygous GLUT1 P485L mutation and were stained for known pluripotency 
markers (see Methods). 
Fig. S6: Mutation-induced gains of dileucine motifs are a significant cause of 
disease. Related to Fig. 7. 
A, A systematic bioinformatic search from the Clinvar Database revealed four 
additional mutations, with pathogenic indications, in cytosolic segments of 
transmembrane proteins that create dileucine motifs. (Depicted here are only 
mutations from Table S4/Clinvar that are classified ‘Pathogenic’ or ‘Conflicting 
interpretations of pathogenicity’, in case ‘pathogenic’ or ‘likely pathogenic’ was 
included in the different interpretations, that had not been found with the Humsavar 
analysis before.) Overlap between Humsavar and Clinvar is: RET_P1039L, 
L1CAM_S1194L, ITPR1_P1059L, RHBDF2_P189L). 
B, Relative frequency of dileucine motif gains in disease mutations (Clinical 
significance levels ‘Pathogenic’, ‘Pathogenic/Likely pathogenic’, or ‘Likely 
pathogenic’) and polymorphisms (Clinical significance levels ‘Benign’, ‘Benign/Likely 
benign’, or ‘Likely benign’) in different disordered regions (IUPred Score >= 0.4) of 
the proteome. Dileucine motif gain is significantly enriched in disordered regions of 
transmembrane proteins. Enrichment becomes more significant when looking only at 
disordered cytoplasmic domains (two-sided Fisher’s exact test).  
C, Comparison of gained motifs in disordered regions of cytoplasmic tails of 
transmembrane proteins reveals the dileucine motif is one of the most significant, 
specific enriched motifs when compared with polymorphisms. (ELM Motif 
LIG_LIR_Nem_3 (-log10(pval)=2.723722 , log2oddsRatio=2.63761) has been taken 
out of graphical representation because it is functional only in nematodes and 
represents a less specific form of LIG_LIR_Gen_1.) 
D, Dileucine containing peptides interact with adaptor proteins. Mutant tails of 
CACNA1H, L1CAM and ITPR1 show increased binding of AP-1 compared to wild-
type tails. Mutant tails of CACNA1H and RHBDF2 show increased binding of AP2 
compared to wild type tails. Tails were tagged with GST to pull-down interaction 
partners from mouse brain lysate. Talin is shown as a negative control and is not 
pulled down from any of the constructs. 
GO Term analysis of subclusters of the peptide-protein interaction network 
composed of significant differential interactions  
180 peptide-protein interactions that passed the LFQ filter and showed significant 
differential SILAC ratios between wild-type and mutant forms of the peptides were 
used to compose a peptide-protein interaction network. Communities (sub-graphs) of 
this network was extracted using the fastgreedy.community function of the igraph R 
package (See Methods). GO term enrichment was calculated for the nodes of each 
subgraph of the network. Within the subgraphs, the edges (interactions) are colored 
differentially depending on whether the interaction is with a mutant or wild-type 
peptide. The peptides are depicted as triangles while the proteins are depicted as 
circles and they are differentially colored. Below the subgraph figure, a bar plot of the 
top 10 enriched GO terms are displayed (differentially colored by the GO term 
category as ‘Biological Process’, ‘Molecular Function’ or ‘Cellular Compartment), in 
which the x-axis shows the log10 p-values corrected for multiple-testing correction 
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